Evidence map›Paper›PMID 40044048›Full record

ArticleThe Journal of allergy and clinical immunology2025

Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.

Brianna T Wachter, Qin Xu, Lihong Shi, Peter D Burbelo, Kathy Myint-Hpu, Pamela L Schwartzberg, Muhammad Tauseef Rehman, Robin L Dewar, Kristin L Boswell, Richard A Koup and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Brianna T WachterLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.
Qin XuLaboratory of Immune System Biology, NIAID, NIH, Bethesda, Md.
Lihong ShiLaboratory of Immune System Biology, NIAID, NIH, Bethesda, Md.
Peter D BurbeloAdeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, NIH, Bethesda, Md.
Kathy Myint-HpuLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md.
Pamela L SchwartzbergLaboratory of Immune System Biology, NIAID, NIH, Bethesda, Md.
Muhammad Tauseef RehmanVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Md.
Robin L DewarVirus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, Md.
Kristin L BoswellImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Md.
Richard A KoupImmunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, Md.
Cihan OguzIntegrated Data Sciences Section, Research Technologies Branch, NIAID, NIH, Bethesda, Md.
Luisa ImbertiSpedali Civili di Brescia, Universita' Degli Studi di Brescia, Brescia, Italy.
Lorenza BellusciDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
Sara PourhashemiDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Md.
Kalpana ManthiramLaboratory of Immune System Biology, NIAID, NIH, Bethesda, Md.
Luigi D NotarangeloLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md. Electronic address: luigi.notarangelo2@nih.gov.
Ottavia M DelmonteLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md. Electronic address: ottavia.delmonte@nih.gov.

Funding

Primary Immune Regulatory Disorders (PIRD): Longitudinal Study of Clinical Presentation, Treatment and OutcomesZIAAI001376 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DELMONTE, OTTAVIA · 2024 to 2025
$219k
Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001376
6 · The paper itself

Abstract

backgroundBivalent coronavirus disease 2019 (COVID) mRNA vaccines encoding Wuhan-1 and Omicron BA.4/BA.5 spike proteins (S) can prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but the quality of adaptive immune responses and the importance of hybrid immunity are not well documented.

objectivesAdaptive immune responses to the bivalent vaccine were studied in 40 healthy participants with (COVID

methodsWe analyzed anti-nucleocapsid protein and anti-S IgG titers and surrogate virus neutralization capacity against variants of concern and assessed SARS-CoV-2-specific B- and T-cell responses by high-dimensional spectral flow cytometry, intracellular cytokine staining assay on stimulation with SARS-CoV-2 peptides, and TRB and IGH repertoire analysis.

resultsThe COVID

conclusionsThe bivalent vaccine induces robust adaptive immune responses against the Omicron variant. Prior SARS-CoV-2 infection provides increased protection, but optimal timing of booster administration after natural infection should be defined to maximize benefits.

Indexed as

Adaptive ImmunityCOVID-19COVID-19 VaccinesSARS-CoV-2Spike Glycoprotein, CoronavirusAdultAntibodies, NeutralizingAntibodies, ViralB-LymphocytesFemaleHumansImmunization, SecondaryImmunoglobulin GMaleMiddle AgedT-LymphocytesAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2B-cell receptor repertoireCOVID-19hybrid immunityOmicron BA.4/BA.5 bivalent mRNA booster vaccinationSARS-CoV-2T-cell receptor repertoirevariants of concern (VOC)

Identifiers

PMID40044048
PMCPMC12145247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.